News - Amylin


Current filters:


Popular Filters

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed


Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility


The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results


A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

Amylin operating loss leaps to over $30 million


US biotech firm Amylin Pharmaceuticals (Nasdaq AMLN): reported financial results for the quarter ended…

AmylinBiotechnologyFinancialMergers & Acquisitions

Investor Icahn slams Amylin for not revealing B-MS bid


Billionaire US investor Carl Icahn has sent a blistering open letter to the board of US biotech company…

AmylinBiotechnologyBristol-Myers SquibbMergers & AcquisitionsPharmaceutical

Byetta cleared for add-on therapy with basal insulin in EU


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) and drug major Eli Lilly (NYSE: LLY) said on Friday…

AmylinByettaDiabetesEli LillyEuropePharmaceuticalRegulation

Amylin 4th-qtr loss widens on charges


US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of…


FDA finally approves Bydureon


There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect


Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq:…

AmylinByettaCardio-vascularDiabetesEli LillyPharmaceuticalResearch

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS


A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

US FDA sets PDUFA action dates for Bydureon and peginesatide


US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Amylin and Takeda drop combo obesity drug development


Amylin Pharmaceuticals (Nasdaq: AMLN) and Japan’s Takeda Pharmaceutical (TSE: 4502) are discontinuing…

AmylinMetabolicsmetreleptinPharmaceuticalpramlintideResearchTakeda Pharmaceuticals

Back to top